Cargando…
Overview of approved CAR‐T therapies, ongoing clinical trials, and its impact on clinical practice
In recent years, we have seen rapid expansion of chimeric antigen receptor T‐cell (CAR‐T) therapies in multiple malignancies. CAR‐T therapy has profoundly altered the treatment landscape of non‐Hodgkin lymphoma, B‐cell acute lymphoblastic leukemia, and multiple myeloma. Currently available CD19 and...
Autores principales: | Sengsayadeth, Salyka, Savani, Bipin N., Oluwole, Olalekan, Dholaria, Bhagirathbhai |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9175669/ https://www.ncbi.nlm.nih.gov/pubmed/35844299 http://dx.doi.org/10.1002/jha2.338 |
Ejemplares similares
-
CAR T cell therapy in solid tumors: A review of current clinical trials
por: Patel, Urvi, et al.
Publicado: (2021) -
Chimeric antigen receptor‐T cell therapies: The changing landscape
por: Sengsayadeth, Salyka M., et al.
Publicado: (2021) -
Role of bridging therapy during chimeric antigen receptor T cell therapy
por: Bhaskar, Shakthi T., et al.
Publicado: (2021) -
Challenges and Advances in Chimeric Antigen Receptor Therapy for Acute Myeloid Leukemia
por: Marvin-Peek, Jennifer, et al.
Publicado: (2022) -
Chimeric antigen receptor T‐cell therapy: Challenges and framework of outpatient administration
por: Gatwood, Katie S., et al.
Publicado: (2021)